PT  - JOURNAL ARTICLE
AU  - TETSUO ISHIZAKI
AU  - JUNICHI MAZAKI
AU  - MASANOBU ENOMOTO
AU  - MASATOSHI SHIGOKA
AU  - KENTA KASAHARA
AU  - TAKAAKI MATSUDO
AU  - HIDEAKI KAWAKITA
AU  - YUICHI NAGAKAWA
AU  - KENJI KATSUMATA
AU  - AKIHIKO TSUCHIDA
TI  - Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
AID  - 10.21873/anticanres.14988
DP  - 2021 Apr 01
TA  - Anticancer Research
PG  - 2157--2163
VI  - 41
IP  - 4
4099  - http://ar.iiarjournals.org/content/41/4/2157.short
4100  - http://ar.iiarjournals.org/content/41/4/2157.full
SO  - Anticancer Res2021 Apr 01; 41
AB  - Background: This study assessed the efficacy and safety of biweekly trifluridine and tipiracil hydrochloride (TAS-102) with bevacizumab combination therapy for patients with metastatic colorectal cancer (mCRC). Patients and Methods: We included 19 patients with mCRC who received TAS-102 and bevacizumab combination therapy biweekly as third-line chemotherapy. The primary endpoint was progression-free survival. Results: Patients had a median age of 73 years and most (73.4%) were men. The median progression-free and overall survival were 5.6 and 11.5 months, respectively. Five (26.3%) patients achieved a response and the disease control rate was 12/19 (63.1%). One patient (5.2%) experienced neutropenia grade 3 or more. The median time from baseline performance status 0/1 to worsening to 2 or more was 10.3 months. Conclusion: Biweekly TAS-102 plus bevacizumab facilitates tumor shrinkage by reducing the incidence of grade 3 or more neutropenia, improving survival, and maintaining performance status. This combination may represent a treatment option for patients with late-stage mCRC receiving third- or later-line therapy.